Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab

Rujiao Liu(Fudan University Shanghai Cancer Center), Zhiyu Chen(Shanghai Medical College of Fudan University), W. ZHANG(Shanghai Medical College of Fudan University), Li‐Xin Qiu(Fudan University Shanghai Cancer Center), Zhanqing Zhang(Shanghai Medical College of Fudan University), Xiaoyan Zhu(Central Hospital of Zibo), Weijian Guo, Mingzhu Huang(Shanghai Medical College of Fudan University), Xiaoying Zhao(Handan College), W. Li(Shanghai Medical College of Fudan University)
Clinical & Translational Oncology
September 30, 2019
10.1007/s12094-019-02215-7
Cited by 17

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
|JAMA|2018|410
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247